IN2012DN03921A - - Google Patents

Download PDF

Info

Publication number: IN2012DN03921A
Authority: IN; India
Prior art keywords: peptide; diabetes; insulin; disorders; glp
Prior art date: 2004-02-11

Application number

Other languages

English (en)

Inventor

Odile Esther Levy

Michael R Hanley

Carolyn M Jodka

Diana Y Lewis

Christopher J Soares

Soumitra S Ghosh

Souza Lawrence J D

David G Parkes

Christine M Mack

Original Assignee

Amylin Pharmaceuticals Inc

Astrazeneca Pharmaceuticals Lp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-02-11

Filing date

2005-02-11

Publication date

2015-09-04

2005-02-11 Application filed by Amylin Pharmaceuticals Inc, Astrazeneca Pharmaceuticals Lp filed Critical Amylin Pharmaceuticals Inc

2015-09-04 Publication of IN2012DN03921A publication Critical patent/IN2012DN03921A/en

Links

206010012601 diabetes mellitus Diseases 0.000 abstract 3
102000004196 processed proteins & peptides Human genes 0.000 abstract 3
108090000765 processed proteins & peptides Proteins 0.000 abstract 3
102000004379 Adrenomedullin Human genes 0.000 abstract 2
101800004616 Adrenomedullin Proteins 0.000 abstract 2
YNXLOPYTAAFMTN-SBUIBGKBSA-N C([C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)C1=CC=C(O)C=C1 Chemical compound C([C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)C1=CC=C(O)C=C1 YNXLOPYTAAFMTN-SBUIBGKBSA-N 0.000 abstract 2
102000055006 Calcitonin Human genes 0.000 abstract 2
108060001064 Calcitonin Proteins 0.000 abstract 2
102000004414 Calcitonin Gene-Related Peptide Human genes 0.000 abstract 2
108090000932 Calcitonin Gene-Related Peptide Proteins 0.000 abstract 2
102400000326 Glucagon-like peptide 2 Human genes 0.000 abstract 2
101800000221 Glucagon-like peptide 2 Proteins 0.000 abstract 2
102400000319 Oxyntomodulin Human genes 0.000 abstract 2
101800001388 Oxyntomodulin Proteins 0.000 abstract 2
108010088847 Peptide YY Proteins 0.000 abstract 2
102100029909 Peptide YY Human genes 0.000 abstract 2
ULCUCJFASIJEOE-NPECTJMMSA-N adrenomedullin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC(=O)N[C@@H]1C(N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CSSC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)[C@@H](C)O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 ULCUCJFASIJEOE-NPECTJMMSA-N 0.000 abstract 2
229960004015 calcitonin Drugs 0.000 abstract 2
BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 abstract 2
TWSALRJGPBVBQU-PKQQPRCHSA-N glucagon-like peptide 2 Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O)[C@@H](C)CC)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=CC=C1 TWSALRJGPBVBQU-PKQQPRCHSA-N 0.000 abstract 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 2
208000030159 metabolic disease Diseases 0.000 abstract 2
PXZWGQLGAKCNKD-DPNMSELWSA-N molport-023-276-326 Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 PXZWGQLGAKCNKD-DPNMSELWSA-N 0.000 abstract 2
208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 2
208000024172 Cardiovascular disease Diseases 0.000 abstract 1
101800001982 Cholecystokinin Proteins 0.000 abstract 1
102100025841 Cholecystokinin Human genes 0.000 abstract 1
208000032928 Dyslipidaemia Diseases 0.000 abstract 1
208000030814 Eating disease Diseases 0.000 abstract 1
108010011459 Exenatide Proteins 0.000 abstract 1
208000019454 Feeding and Eating disease Diseases 0.000 abstract 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
206010020772 Hypertension Diseases 0.000 abstract 1
102000004877 Insulin Human genes 0.000 abstract 1
108090001061 Insulin Proteins 0.000 abstract 1
206010022489 Insulin Resistance Diseases 0.000 abstract 1
102000036770 Islet Amyloid Polypeptide Human genes 0.000 abstract 1
108010041872 Islet Amyloid Polypeptide Proteins 0.000 abstract 1
108010092277 Leptin Proteins 0.000 abstract 1
102000016267 Leptin Human genes 0.000 abstract 1
208000017170 Lipid metabolism disease Diseases 0.000 abstract 1
208000008589 Obesity Diseases 0.000 abstract 1
206010067584 Type 1 diabetes mellitus Diseases 0.000 abstract 1
JUFFVKRROAPVBI-PVOYSMBESA-N chembl1210015 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N[C@H]1[C@@H]([C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@]3(O[C@@H](C[C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C3)C(O)=O)O2)O)[C@@H](CO)O1)NC(C)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 JUFFVKRROAPVBI-PVOYSMBESA-N 0.000 abstract 1
239000003795 chemical substances by application Substances 0.000 abstract 1
229940107137 cholecystokinin Drugs 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
208000035475 disorder Diseases 0.000 abstract 1
235000014632 disordered eating Nutrition 0.000 abstract 1
229960001519 exenatide Drugs 0.000 abstract 1
208000004104 gestational diabetes Diseases 0.000 abstract 1
239000008103 glucose Substances 0.000 abstract 1
230000003054 hormonal effect Effects 0.000 abstract 1
229940088597 hormone Drugs 0.000 abstract 1
239000005556 hormone Substances 0.000 abstract 1
229940125396 insulin Drugs 0.000 abstract 1
230000003914 insulin secretion Effects 0.000 abstract 1
SFVVQRJOGUKCEG-UHFFFAOYSA-N isoechinatine Natural products C1CC(O)C2C(COC(=O)C(O)(C(C)O)C(C)C)=CCN21 SFVVQRJOGUKCEG-UHFFFAOYSA-N 0.000 abstract 1
229940039781 leptin Drugs 0.000 abstract 1
NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 abstract 1
235000020824 obesity Nutrition 0.000 abstract 1
229920001184 polypeptide Polymers 0.000 abstract 1
GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 abstract 1
230000002265 prevention Effects 0.000 abstract 1
IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 abstract 1
SFVVQRJOGUKCEG-OPQSFPLASA-N β-MSH Chemical compound C1C[C@@H](O)[C@H]2C(COC(=O)[C@@](O)([C@@H](C)O)C(C)C)=CCN21 SFVVQRJOGUKCEG-OPQSFPLASA-N 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/595—Gastrins; Cholecystokinins [CCK]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Endocrinology (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Diabetes (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Toxicology (AREA)
Hematology (AREA)
Obesity (AREA)
Cardiology (AREA)
Vascular Medicine (AREA)
Heart & Thoracic Surgery (AREA)
Emergency Medicine (AREA)
Urology & Nephrology (AREA)
Child & Adolescent Psychology (AREA)
Immunology (AREA)
Epidemiology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)

IN3921DEN2012 2004-02-11 2005-02-11 IN2012DN03921A (it)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US54340704P	2004-02-11	2004-02-11
PCT/US2005/004178 WO2005077072A2 (en)	2004-02-11	2005-02-11	Hybrid polypeptides with selectable properties

Publications (1)

Publication Number	Publication Date
IN2012DN03921A true IN2012DN03921A (it)	2015-09-04

Family

ID=34860419

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IN3921DEN2012 IN2012DN03921A (it)	2004-02-11	2005-02-11

Country Status (14)

Country	Link
US (1)	US20060094652A1 (it)
EP (4)	EP2422807A3 (it)
JP (2)	JP2007525495A (it)
KR (3)	KR20140011431A (it)
CN (3)	CN102174115B (it)
AU (1)	AU2005211755B2 (it)
BR (1)	BRPI0507594A (it)
CA (2)	CA2555877C (it)
IL (1)	IL177229A0 (it)
IN (1)	IN2012DN03921A (it)
NZ (2)	NZ548978A (it)
RU (1)	RU2378285C2 (it)
WO (1)	WO2005077072A2 (it)
ZA (1)	ZA200607190B (it)

Families Citing this family (103)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7138486B2 (en) *	1986-05-05	2006-11-21	The General Hospital Corporation	Insulinotropic hormone derivatives and uses thereof
US20050272652A1 (en)	1999-03-29	2005-12-08	Gault Victor A	Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
US20090281032A1 (en) *	2001-03-01	2009-11-12	Peter Raymond Flatt	Modified CCK peptides
US7731947B2 (en)	2003-11-17	2010-06-08	Intarcia Therapeutics, Inc.	Composition and dosage form comprising an interferon particle formulation and suspending vehicle
US8076288B2 (en)	2004-02-11	2011-12-13	Amylin Pharmaceuticals, Inc.	Hybrid polypeptides having glucose lowering activity
US8114958B2 (en) *	2004-02-11	2012-02-14	Amylin Pharmaceuticals, Inc.	Amylin family peptides
US7399744B2 (en) *	2004-03-04	2008-07-15	Amylin Pharmaceuticals, Inc.	Methods for affecting body composition
WO2006049681A2 (en) *	2004-08-30	2006-05-11	Bayer Pharmaceuticals Corporation	Selective neuropeptide y2 receptor agonists
BRPI0516574A (pt) *	2004-10-08	2008-09-16	Amylin Pharmaceuticals Inc	análogos do polipeptìdeo-6 da famìlia amilina (afp-6) e métodos para preparar e usar os mesmos
WO2006083761A2 (en)	2005-02-03	2006-08-10	Alza Corporation	Solvent/polymer solutions as suspension vehicles
US11246913B2 (en)	2005-02-03	2022-02-15	Intarcia Therapeutics, Inc.	Suspension formulation comprising an insulinotropic peptide
US8052996B2 (en)	2005-02-03	2011-11-08	Intarcia Therapeutics, Inc.	Two-piece, internal-channel osmotic delivery system flow modulator
US8263545B2 (en)	2005-02-11	2012-09-11	Amylin Pharmaceuticals, Inc.	GIP analog and hybrid polypeptides with selectable properties
WO2007022123A2 (en) *	2005-08-11	2007-02-22	Amylin Pharmaceuticals, Inc.	Hybrid polypeptides with selectable properties
EA011653B1 (ru)	2005-02-11	2009-04-28	Амилин Фармасьютикалз, Инк.	Аналоги и гибридные полипептиды gip с избираемыми свойствами
EP1891106A2 (en) *	2005-05-05	2008-02-27	Cadila Healthcare Ltd.	Novel compounds as glp-i agonists
WO2007014051A2 (en) *	2005-07-22	2007-02-01	Amylin Pharmaceuticals, Inc.	Use of amylin and amylin agonists as cardioprotective or myoprotective agents
MX2008002028A (es) *	2005-08-11	2008-03-27	Amylin Pharmaceuticals Inc	Polipeptidos hibridos con propiedades de seleccion.
EP2330125A3 (en)	2005-08-11	2012-12-12	Amylin Pharmaceuticals, Inc.	Hybrid polypeptides with selectable properties
EP2045265B1 (en)	2005-09-22	2012-11-21	Biocompatibles Uk Ltd.	GLP-1 (Glucagon-like peptide-1) fusion polypeptides with increased peptidase resistance
WO2007055743A2 (en) *	2005-11-01	2007-05-18	Amylin Pharmaceuticals, Inc.	Treatment of obesity and related disorders
EP1954313A1 (en) *	2005-11-01	2008-08-13	Amylin Pharmaceuticals, Inc.	Treatment of obesity and related disorders
AU2007221366B2 (en) *	2006-02-22	2012-08-23	Msd Italia S.R.L.	Oxyntomodulin derivatives
US8486890B2 (en)	2006-03-15	2013-07-16	Novo Nordisk A/S	Amylin derivatives
WO2007109354A2 (en) *	2006-03-21	2007-09-27	Amylin Pharmaceuticals, Inc.	Peptide-peptidase inhibitor conjugates and methods of using same
ATE444741T1 (de)	2006-05-10	2009-10-15	Biocompatibles Uk Ltd	Glp-1 peptide enthaltende kugelförmige mikrokapseln, deren produktion und deren verwendung
WO2008005527A2 (en) *	2006-07-06	2008-01-10	Amylin Pharmaceuticals, Inc.	Glucagon-like peptides and uses thereof
WO2008007071A1 (en)	2006-07-10	2008-01-17	Cenes Limited	Short-acting benzodiazepine salts and their polymorphic forms
PT2359808E (pt)	2006-08-09	2013-08-28	Intarcia Therapeutics Inc	Sistemas de entrega osmótica e montagens de pistão
EP2057188B1 (en) *	2006-08-17	2013-07-31	Amylin Pharmaceuticals, LLC	Dpp-iv resistant gip hybrid polypeptides with selectable properties
EP1972349A1 (en) *	2007-03-21	2008-09-24	Biocompatibles UK Limited	GLP-1 fusion peptides conjugated to polymer(s), their production and use
PL2157967T3 (pl)	2007-04-23	2013-06-28	Intarcia Therapeutics Inc	Formulacje zawiesinowe peptydów insulinotropowych i ich zastosowania
JP2010532323A (ja) *	2007-07-06	2010-10-07	セラテクノロジーズインコーポレイテッド	アルファ−メラニン細胞刺激ホルモン（アルファ−ｍｓｈ）および心房性ナトリウム利尿タンパク質（ａｎｐ）の二機能性融合タンパク質ならびに高血圧および急性腎臓損傷における使用
CA2726861C (en)	2008-02-13	2014-05-27	Intarcia Therapeutics, Inc.	Devices, formulations, and methods for delivery of multiple beneficial agents
WO2009143285A2 (en)	2008-05-21	2009-11-26	Amylin Pharmaceuticals, Inc.	Exendins to lower cholestrol and triglycerides
CN102197049B (zh)	2008-10-21	2015-03-25	诺沃-诺迪斯克有限公司	胰岛淀粉样多肽衍生物
JO3382B1 (ar)	2008-12-23	2019-03-13	Amgen Inc	أجسام مضادة ترتبط مع مستقبل cgrp بشري
WO2010118384A2 (en)	2009-04-10	2010-10-14	Amylin Pharmaceuticals, Inc.	Amylin agonist compounds for estrogen-deficient mammals
WO2010138671A1 (en)	2009-05-28	2010-12-02	Amylin Pharmaceuticals, Inc.	Glp-1 receptor agonist compounds for sleep enhancement
HUE035862T2 (en)	2009-09-28	2018-05-28	Intarcia Therapeutics Inc	Rapid establishment and/or termination of substantial steady-state drug delivery
US20140066370A1 (en)	2009-11-23	2014-03-06	Amylin Pharmaceuticals, Llc	Polypeptide Conjugate
GB201001333D0 (en)	2010-01-27	2010-03-17	Imp Innovations Ltd	Novel compounds and their effects on feeding behaviour
US9089538B2 (en) *	2010-04-27	2015-07-28	Zealand Pharma A/S	Peptide conjugates of GLP-1 receptor agonists and gastrin and their use
EP2450039A1 (en)	2010-11-08	2012-05-09	PAION UK Ltd.	Dosing regimen for sedation with CNS 7056 (Remimazolam)
EP3326620B1 (en)	2010-12-16	2020-03-04	Novo Nordisk A/S	Solid compositions comprising a glp-1 agonist and a salt of n-(8-(2- hydroxybenzoyl)amino)caprylic acid
WO2012088157A2 (en)	2010-12-22	2012-06-28	Amylin Pharmaceuticals, Inc.	Glp-1 receptor agonists for islet cell transplantation
GB201101459D0 (en)	2011-01-27	2011-03-16	Imp Innovations Ltd	Novel compounds and thier effects on fedding behaviour
US20120208755A1 (en)	2011-02-16	2012-08-16	Intarcia Therapeutics, Inc.	Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
EP2714069A4 (en)	2011-05-25	2015-06-24	Amylin Pharmaceuticals Llc	LONG-TERM CONJUGATES WITH TWO HORMONES
US9259477B2 (en) *	2011-11-03	2016-02-16	Zealand Pharma A/S	GLP-1 receptor agonist peptide gastrin conjugates
CN104203266B (zh)	2012-03-22	2017-12-26	诺和诺德股份有限公司	Glp‑1肽组合物及其制备
UA116217C2 (uk)	2012-10-09	2018-02-26	Санофі	Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
EA031428B1 (ru)	2012-12-21	2018-12-28	Санофи	Функционализированные производные эксендина-4
AR094963A1 (es)	2013-03-04	2015-09-09	Ono Pharmaceutical Co	Reacción de oxidación excelente en el índice de conversión
RU2678134C2 (ru) *	2013-03-14	2019-01-23	Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн	Конъюгаты инсулин-инкретин
SI2991671T1 (sl)	2013-05-02	2018-10-30	Novo Nordisk A/S	Peroralno odmerjanje spojin GLP-1
KR102310392B1 (ko)	2013-11-06	2021-10-13	질랜드 파마 에이/에스	글루카곤-ｇｌｐ-1-ｇｉｐ 삼원 효능제 화합물
WO2015067715A2 (en)	2013-11-06	2015-05-14	Zealand Pharma A/S	Gip-glp-1 dual agonist compounds and methods
MX369818B (es)	2013-11-15	2019-11-22	Novo Nordisk As	Compuestos selectivos de peptido yy (pyy) y usos de los mismos.
EP3068795B1 (en)	2013-11-15	2019-03-06	Novo Nordisk A/S	Hpyy(1-36) having a beta-homoarginine substitution at position 35
TW201609797A (zh)	2013-12-13	2016-03-16	賽諾菲公司	雙重ｇｌｐ－１／升糖素受體促效劑
EP3080150B1 (en)	2013-12-13	2018-08-01	Sanofi	Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
EP3080152A1 (en)	2013-12-13	2016-10-19	Sanofi	Non-acylated exendin-4 peptide analogues
TW201609799A (zh)	2013-12-13	2016-03-16	賽諾菲公司	雙重ｇｌｐ－１／ｇｉｐ受體促效劑
CN103665148B (zh) *	2013-12-17	2016-05-11	中国药科大学	一种可口服给药的降糖多肽及其制法和用途
TW201625670A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625668A (zh)	2014-04-07	2016-07-16	賽諾菲公司	作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625669A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
US9932381B2 (en)	2014-06-18	2018-04-03	Sanofi	Exendin-4 derivatives as selective glucagon receptor agonists
CA2960756C (en)	2014-09-15	2023-08-01	Amgen Inc.	Bi-specific anti-cgrp receptor/pac1 receptor antigen binding proteins and uses thereof
US9889085B1 (en)	2014-09-30	2018-02-13	Intarcia Therapeutics, Inc.	Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
MX381640B (es)	2014-10-29	2025-03-04	Zealand Pharma As	Metodos y compuestos agonistas de gip.
MX2017011182A (es)	2015-03-18	2018-06-06	Zealand Pharma As	Analogos de amilina.
JOP20200116A1 (ar)	2015-04-24	2017-06-16	Amgen Inc	طرق لعلاج أو الوقاية من الصداع النصفي
MX2017015504A (es)	2015-06-03	2018-05-15	Intarcia Therapeutics Inc	Sistemas de colocacion y remoción de implante.
AR105319A1 (es)	2015-06-05	2017-09-27	Sanofi Sa	Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
CA2988500A1 (en)	2015-06-12	2016-12-15	Novo Nordisk A/S	Selective pyy compounds and uses thereof
TW201706291A (zh)	2015-07-10	2017-02-16	賽諾菲公司	作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
CR20180378A (es)	2015-12-23	2018-12-06	Amgen Inc	Método para tratar o mejorar trastornos metabólicos con proteínas de unión para el receptor peptídico inhibidor gástrico (gipr) en combinación con agosnistas de glp-1
CA3024479A1 (en)	2016-05-16	2017-11-23	Intarcia Therapeutics, Inc.	Glucagon-receptor selective polypeptides and methods of use thereof
USD840030S1 (en)	2016-06-02	2019-02-05	Intarcia Therapeutics, Inc.	Implant placement guide
USD860451S1 (en)	2016-06-02	2019-09-17	Intarcia Therapeutics, Inc.	Implant removal tool
ES2965087T3 (es) *	2016-09-02	2024-04-10	Soares Christopher J	Uso de antagonistas de receptor de CGRP en el tratamiento de glaucoma
AR109514A1 (es)	2016-09-09	2018-12-19	Zealand Pharma As	Análogos de amilina
EP3551202B1 (en)	2016-12-06	2024-01-24	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods of enhancing the potency of incretin-based drugs in subjects in need thereof
KR102502040B1 (ko)	2016-12-09	2023-02-24	질랜드 파마 에이/에스	아실화 glp-1/glp-2 이중 효능제
CN110225762A (zh)	2017-01-03	2019-09-10	因塔西亚制药公司	包括glp-1受体激动剂的连续施用和药物的共同施用的方法
JOP20190177A1 (ar)	2017-01-17	2019-07-16	Amgen Inc	طريقة لعلاج أو تحسين اضطرابات أيضية باستخدام مساعدات مستقبل glp-1 مقترنة بمناهضات لمستقبل ببتيد مثبط معوي (gipr)
PE20200013A1 (es)	2017-06-20	2020-01-06	Amgen Inc	Metodo para tratar o mejorar trastornos metabolicos con proteinas de union para el receptor peptidico inhibidor gastrico (gipr) en combinacion con agonistas de glp-1
JP6898518B2 (ja)	2018-02-02	2021-07-07	ノヴォノルディスクアー／エス	Ｇｌｐ−１アゴニスト、ｎ−（８−（２−ヒドロキシベンゾイル）アミノ）カプリル酸の塩及び滑沢剤を含む固形組成物
KR20200139720A (ko)	2018-04-02	2020-12-14	암젠 인크	에레누맙 조성물 및 이의 용도
US11780900B2 (en)	2018-04-25	2023-10-10	Janssen Sciences Ireland Unlimited Company	Glucagon like peptide 1 (GLP-1) fusion peptide coupled cyclic peptide tyrosine tyrosine conjugates and uses thereof
TWI847981B (zh) *	2018-04-25	2024-07-11	比利時商健生藥品公司	類升糖素肽1 (glp-1)融合肽偶合環狀酪酪肽接合物及其用途
US11970523B2 (en) *	2018-07-25	2024-04-30	China Pharmaceutical University	Long-acting oxyntomodulin hybrid peptide, preparation method therefor, and application thereof
CA3116023A1 (en)	2018-10-11	2020-04-16	Intarcia Therapeutics, Inc.	Human amylin analog polypeptides and methods of use
MX2021010737A (es)	2019-03-08	2021-09-28	Amgen Inc	Terapia de combinacion por factor de diferenciacion del crecimiento 15.
US20220204581A1 (en) *	2019-04-01	2022-06-30	Syracuse University	Monomeric peptide multi-agonist targeting the glp1 receptor and npy receptors
KR102288716B1 (ko) *	2019-10-30	2021-08-12	경상남도	항비만 효능을 갖는 펩타이드 및 이의 용도
PH12022551101A1 (en)	2019-11-11	2023-11-13	Boehringer Ingelheim Int	Npy2 receptor agonists
KR20230045088A (ko)	2020-08-07	2023-04-04	베링거 인겔하임 인터내셔날 게엠베하	가용성 npy2 수용체 작용제
TW202440619A (zh)	2020-12-18	2024-10-16	丹麥商諾佛儂迪克股份有限公司	Glp-1及澱粉素受體之共促效劑
CN113929737B (zh) *	2021-10-20	2024-07-23	中国科学院香港创新研究院再生医学与健康创新中心	一种多肽及其作为cck受体激动剂/拮抗剂的应用
WO2024123812A1 (en)	2022-12-05	2024-06-13	Shattuck Labs, Inc.	Fusion proteins for the treatment of cardiometabolic diseases

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3490597A (en)	1966-07-22	1970-01-20	Purolator Products Inc	Cover plate for spin-on-filter
DE3065460D1 (en)	1979-07-28	1983-12-08	Beecham Group Plc	Benzocycloheptapyrrolealkanoic acids and their derivatives, processes for their preparation and pharmaceutical compositions containing them
US4397780A (en) *	1982-02-12	1983-08-09	Armour Pharmaceutical Company	Leucine22 -calcitonin
US4401593A (en)	1982-02-12	1983-08-30	Armour Pharmaceutical Company	Glycine - 8 calcitonin
US6936694B1 (en)	1982-05-06	2005-08-30	Intermune, Inc.	Manufacture and expression of large structural genes
US4414149A (en)	1983-03-04	1983-11-08	Armour Pharmaceutical Company	Glycine8 -D-arginine24 calcitonin
US4497731A (en)	1983-04-04	1985-02-05	Armour Pharmaceutical Company	Glycine 8-des-tyrosine 22 calcitonin
US4495097A (en)	1983-04-04	1985-01-22	Armour Pharmaceutical Company	Des-serine2 -glycine8 calcitonin
US5188666A (en) *	1983-06-30	1993-02-23	Boccardo Victor N	Paint removing compositions and methods for the manufacture and use thereof
US4597900A (en) *	1983-08-22	1986-07-01	Armour Pharmaceutical Co.	Des2 -glycine8 -des22 -calcitonin
US4537716A (en) *	1983-12-05	1985-08-27	Armour Pharmaceutical Co.	Des-serine2 or des-glycine2 -leucine22 calcitonin
US4604238A (en)	1984-12-10	1986-08-05	Armour Pharmaceutical Company	Analogs of calcitonin
US4606856A (en)	1985-03-18	1986-08-19	Seyler Jay K	[Des-1-amino, 8-glycine]calcitonin
US4652627A (en)	1985-08-16	1987-03-24	Kempe Tomas G	Calcitonin analogs with C-terminal D-amino acid substituents
US4687839A (en)	1985-12-23	1987-08-18	Kempe Tomas G	Calcitonin gene related peptide analogs with C-terminal D-amino acid substituents
US4697002A (en)	1985-12-23	1987-09-29	Kempe Tomas G	Calcitonin gene related peptide analogs with amino acid subdstituents at the penultimate position 36
DE68929566D1 (de)	1988-05-13	2010-01-28	Amgen Inc	Verfahren zur Isolierung und Reinigung von G-CSF
JP2989002B2 (ja)	1988-12-22	1999-12-13	キリン―アムジエン・インコーポレーテツド	化学修飾顆粒球コロニー刺激因子
DE69129226T2 (de)	1990-01-24	1998-07-30	Douglas I. Woodside Calif. Buckley	Glp-1-analoga verwendbar in der diabetesbehandlung
US5545618A (en)	1990-01-24	1996-08-13	Buckley; Douglas I.	GLP-1 analogs useful for diabetes treatment
US5234906A (en)	1991-01-10	1993-08-10	Amylin Pharmaceuticals, Inc.	Hyperglycemic compositions
HU222249B1 (hu)	1991-03-08	2003-05-28	Amylin Pharmaceuticals Inc.	Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására
US5445781A (en)	1991-08-28	1995-08-29	Centro Sviluppo Settori Impiego S.R.L.	Process for the injection molding of non-precatalyzed polymerizable resins at high-pressure and flow
SG52542A1 (en) *	1993-03-29	1998-09-28	Univ Cincinnati	Analogs of peptide yy and uses thereof
US5424286A (en)	1993-05-24	1995-06-13	Eng; John	Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
US5814316A (en) *	1994-08-05	1998-09-29	Wisconsin Alumni Research Foundation	Compound to mimick a naturally occurring peptide's effect
US6309853B1 (en)	1994-08-17	2001-10-30	The Rockfeller University	Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US5824784A (en)	1994-10-12	1998-10-20	Amgen Inc.	N-terminally chemically modified protein compositions and methods
US5512549A (en)	1994-10-18	1996-04-30	Eli Lilly And Company	Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
US5574010A (en)	1994-11-14	1996-11-12	The Regents Of The University Of California	Treatment of pancreatic tumors with peptide YY and analogs thereof
US5521283A (en) *	1995-01-31	1996-05-28	Eli Lilly And Company	Anti-obesity proteins
US5532336A (en) *	1995-01-31	1996-07-02	Eli Lilly And Company	Anti-obesity proteins
US5739106A (en) *	1995-06-07	1998-04-14	Rink; Timothy J.	Appetite regulating compositions
PL324284A1 (en)	1995-06-30	1998-05-11	Lilly Co Eli	Methods of treating diabetes
US5773416A (en)	1995-10-25	1998-06-30	The Regents Of The University Of California	Methods for restoring or enhancing reproductive function in reproductively impaired hosts
WO1997026321A2 (en) *	1996-01-19	1997-07-24	Board Of Regents, The University Of Texas System	Recombinant expression of proteins from secretory cell lines
ES2260784T3 (es)	1996-01-23	2006-11-01	Indevus Pharmaceuticals, Inc.	Metodos de utilizacion del gen obese y su producto genico para estimular el desarrolo hematopoyetico.
TR199802534T2 (xx)	1996-06-06	1999-03-22	Smithkline Beecham P.L.C.	Leptin (OB Protein) fragmanlar�
US5686511A (en)	1996-06-28	1997-11-11	The Valspar Corporation	Esterifying epoxy resin with carboxyl polymer and quenching
US6277819B1 (en) *	1996-08-30	2001-08-21	Eli Lilly And Company	Use of GLP-1 or analogs in treatment of myocardial infarction
PL332458A1 (en)	1996-09-20	1999-09-13	Hoechst Ag	Application of leptin antagonists in treating insulin resistance in cases of diabeted of type ii
WO1998018486A1 (en)	1996-10-25	1998-05-07	Icogen Corporation	Use of leptin to stimulate hematopoiesis
PT1629849E (pt) *	1997-01-07	2013-07-09	Amylin Pharmaceuticals Llc	Composições farmacêuticas que compreendem exendinas e seus agonistas
JP2001512483A (ja)	1997-02-25	2001-08-21	イーライリリーアンドカンパニー	レプチンレセプターリガンドによる不妊症の治療
IL120733A0 (en)	1997-04-29	1997-08-14	Yeda Res & Dev	Leptin as an inhibitor of cell proliferation
US7910548B2 (en)	1997-06-06	2011-03-22	Amylin Pharmaceuticals, Inc.	Methods for treating obesity
HUP0003428A3 (en)	1997-06-06	2001-12-28	Smithkline Beecham Plc	Use of leptin antagonists for the treatment of diabetes
NZ502592A (en)	1997-08-08	2002-03-28	Amylin Pharmaceuticals Inc	Exendin agonist peptides and their use in the treatment of type I and II diabetes
DK1032587T4 (da)	1997-11-14	2013-04-08	Amylin Pharmaceuticals Llc	Hidtil ukendte exendinagonist-forbindelser
AU757748B2 (en)	1997-11-14	2003-03-06	Amylin Pharmaceuticals, Inc.	Novel exendin agonist compounds
DE60045030D1 (de) *	1999-02-10	2010-11-11	Curis Inc	Peptid yy (pyy) zur behandlung von glukose stoffwechselkrankheiten
US7745216B2 (en) *	1999-02-10	2010-06-29	Curis, Inc.	Methods and reagents for treating glucose metabolic disorders
US6162260A (en)	1999-05-24	2000-12-19	Novo Nordisk Biochem North America, Inc.	Single-bath biopreparation and dyeing of textiles
EP1076066A1 (en)	1999-07-12	2001-02-14	Zealand Pharmaceuticals A/S	Peptides for lowering blood glucose levels
US6528486B1 (en)	1999-07-12	2003-03-04	Zealand Pharma A/S	Peptide agonists of GLP-1 activity
US6734166B1 (en)	2000-02-08	2004-05-11	North Carolina State University	Method of reducing aluminum levels in the central nervous system
US6602997B2 (en)	2000-04-27	2003-08-05	Shin-Etsu Bio, Inc.	Whole cell and cell-debris polysaccharide
WO2002046227A2 (en) *	2000-12-07	2002-06-13	Eli Lilly And Company	Glp-1 fusion proteins
US8273713B2 (en) *	2000-12-14	2012-09-25	Amylin Pharmaceuticals, Llc	Methods of treating obesity using PYY[3-36]
GB0121709D0 (en)	2001-09-07	2001-10-31	Imp College Innovations Ltd	Food inhibition agent
PL205971B1 (pl)	2001-09-24	2010-06-30	Imp Innovations Ltd	Zastosowanie PYY₃-₃₆ do wytwarzania leku na ograniczanie apetytu, zmniejszenie otyłości lub do zapobiegania otyłości
JP4733922B2 (ja)	2002-01-10	2011-07-27	インペリアル・イノベ−ションズ・リミテッド	摂食行動の修正
US20060122106A1 (en)	2002-06-14	2006-06-08	Amylin Pharmaceuticals, Inc	Prevention and/or treatment of inflammatory bowel disease using pyy or agonists thereof
WO2004039832A2 (en)	2002-10-31	2004-05-13	Albany Medical College	Leptin-related peptides
US20040209803A1 (en)	2002-12-19	2004-10-21	Alain Baron	Compositions for the treatment and prevention of nephropathy
CA2525168A1 (en) *	2003-05-14	2004-12-02	Emisphere Technologies, Inc.	Compositions for delivering peptide yy and pyy agonists
JP6226510B2 (ja)	2012-01-27	2017-11-08	キヤノン株式会社	画像処理システム、処理方法及びプログラム
ITMI20130325A1 (it)	2013-03-05	2014-09-06	Telecom Italia Spa	Metodo per misurare e monitorare il livello di accesso a dati personali generati da risorse di un dispositivo d'utente
US9602308B2 (en)	2014-06-23	2017-03-21	International Business Machines Corporation	Servicing packets in a virtual network and a software-defined network (SDN)
US9816387B2 (en)	2014-09-09	2017-11-14	United Technologies Corporation	Attachment faces for clamped turbine stator of a gas turbine engine
CA2914090C (en)	2015-03-31	2023-08-01	Allen-Vanguard Corporation	Frequency and time domain streaming receiver
US9601471B2 (en)	2015-04-23	2017-03-21	Apple Inc.	Three layer stack structure
US9714199B2 (en)	2015-09-17	2017-07-25	I P Creations Limited	Concealed amalgamated explosive neutralizer and method of manufacture

2005
- 2005-02-11 IN IN3921DEN2012 patent/IN2012DN03921A/en unknown
- 2005-02-11 US US11/055,093 patent/US20060094652A1/en not_active Abandoned
- 2005-02-11 BR BRPI0507594-7A patent/BRPI0507594A/pt not_active IP Right Cessation
- 2005-02-11 CA CA2555877A patent/CA2555877C/en not_active Expired - Fee Related
- 2005-02-11 RU RU2006132294/04A patent/RU2378285C2/ru not_active IP Right Cessation
- 2005-02-11 WO PCT/US2005/004178 patent/WO2005077072A2/en active Application Filing
- 2005-02-11 EP EP20110176632 patent/EP2422807A3/en not_active Withdrawn
- 2005-02-11 KR KR1020147001171A patent/KR20140011431A/ko not_active Ceased
- 2005-02-11 NZ NZ548978A patent/NZ548978A/en not_active IP Right Cessation
- 2005-02-11 KR KR1020127032622A patent/KR101427024B1/ko not_active Expired - Fee Related
- 2005-02-11 EP EP11176630A patent/EP2422806A3/en not_active Withdrawn
- 2005-02-11 CN CN201110061194.2A patent/CN102174115B/zh not_active Expired - Fee Related
- 2005-02-11 CA CA2849552A patent/CA2849552A1/en not_active Abandoned
- 2005-02-11 AU AU2005211755A patent/AU2005211755B2/en not_active Ceased
- 2005-02-11 JP JP2006553217A patent/JP2007525495A/ja active Pending
- 2005-02-11 CN CN201410138746.9A patent/CN103897066A/zh active Pending
- 2005-02-11 EP EP11176627A patent/EP2417980A1/en not_active Withdrawn
- 2005-02-11 KR KR1020127004103A patent/KR20120034237A/ko not_active Application Discontinuation
- 2005-02-11 CN CN2005800120093A patent/CN1961000B/zh not_active Expired - Fee Related
- 2005-02-11 EP EP05722892.6A patent/EP1718665B1/en not_active Expired - Lifetime
- 2005-02-11 NZ NZ579621A patent/NZ579621A/en not_active IP Right Cessation
2006
- 2006-08-02 IL IL177229A patent/IL177229A0/en unknown
- 2006-08-29 ZA ZA200607190A patent/ZA200607190B/en unknown
2011
- 2011-06-21 JP JP2011137394A patent/JP5580784B2/ja not_active Expired - Fee Related

Also Published As

Publication number	Publication date
KR101427024B1 (ko)	2014-08-05
EP2422806A3 (en)	2012-06-13
EP2422806A2 (en)	2012-02-29
RU2006132294A (ru)	2008-03-20
EP1718665A4 (en)	2008-05-14
CA2555877C (en)	2015-11-24
CA2555877A1 (en)	2005-08-25
CN102174115B (zh)	2014-05-14
AU2005211755B2 (en)	2012-03-15
WO2005077072A3 (en)	2006-03-02
CN102174115A (zh)	2011-09-07
IL177229A0 (en)	2006-12-10
EP1718665A2 (en)	2006-11-08
ZA200607190B (en)	2007-11-28
KR20130010086A (ko)	2013-01-25
JP2007525495A (ja)	2007-09-06
EP2422807A3 (en)	2012-05-30
KR20140011431A (ko)	2014-01-28
US20060094652A1 (en)	2006-05-04
NZ579621A (en)	2011-03-31
CA2849552A1 (en)	2005-08-25
EP2417980A1 (en)	2012-02-15
RU2378285C2 (ru)	2010-01-10
CN1961000A (zh)	2007-05-09
AU2005211755A1 (en)	2005-08-25
CN1961000B (zh)	2011-05-04
EP2422807A2 (en)	2012-02-29
CN103897066A (zh)	2014-07-02
WO2005077072A2 (en)	2005-08-25
JP5580784B2 (ja)	2014-08-27
JP2011219488A (ja)	2011-11-04
KR20120034237A (ko)	2012-04-10
BRPI0507594A (pt)	2007-07-03
EP1718665B1 (en)	2013-04-10
NZ548978A (en)	2009-10-30

Publication	Publication Date	Title
IN2012DN03921A (it)	2015-09-04
Zheng et al.	2024	Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
JP6379300B2 (ja)	2018-08-22	ＧＬＰ及び免疫グロブリンハイブリッドＦｃ融合ポリペプチド及びその用途
Madsbad	2016	Review of head‐to‐head comparisons of glucagon‐like peptide‐1 receptor agonists
Lovshin et al.	2009	Incretin-based therapies for type 2 diabetes mellitus
Gupta	2013	Glucagon-like peptide-1 analogues: an overview
Aroda et al.	2011	The safety and tolerability of GLP‐1 receptor agonists in the treatment of type 2 diabetes: a review
Kim et al.	2008	The role of incretins in glucose homeostasis and diabetes treatment
Holst et al.	2017	Semaglutide seems to be more effective the other GLP-1Ras
ZA202106369B (en)	2025-01-29	Gip/glp1 co-agonist compounds
ZA200606153B (en)	2007-12-27	Intranasal administration of glucose-regulating peptides
Cho et al.	2013	Clinical application of glucagon-like peptide 1 receptor agonists for the treatment of type 2 diabetes mellitus
NO20074545L (no)	2007-11-09	GIP-analog og hybridpolypeptid med selekterbare egenskaper
WO2006024275A3 (de)	2006-11-30	Erfindung betreffend glp-1 und exendin
Dharmalingam et al.	2011	Liraglutide: A review of its therapeutic use as a once daily GLP-1 analog for the management of type 2 diabetes mellitus
CA3107344A1 (en)	2020-01-30	Methods of using a gip/glp1 co-agonist for therapy
TW201138811A (en)	2011-11-16	Peptide conjugates
Tanaka et al.	2011	The role of incretins in salt-sensitive hypertension: the potential use of dipeptidyl peptidase-IV inhibitors
Spezani et al.	2022	The current significance and prospects for the use of dual receptor agonism GLP-1/Glucagon
MX2022009149A (es)	2022-12-15	Compuestos coagonistas de gip/glp1.
Ruscica et al.	2017	Non-insulin anti-diabetic drugs: An update on pharmacological interactions
Will et al.	2017	Gut check on diabesity: leveraging gut mechanisms for the treatment of type 2 diabetes and obesity
JP2019514908A5 (it)	2020-06-11
Gong et al.	2024	Glucagon-like peptide-1 analogs: Miracle drugs are blooming?
Wu et al.	2023	Factors associated with gastrointestinal side effects after liraglutide treatment for type 2 diabetes